SCHEMBL6575838

SCHEMBL6575838

COC(=O)C1=CCCCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
GSTP1 P09211 2/20 0.41
TSHR P16473 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRM3 P20309 2/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
HTT P42858 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8569125 0.88 PTPN1 (0.41) TSHRL3MBTL1CHRM3ALDH1A1MAPT
SCHEMBL819613 0.81 CHRM3 (0.42) HDAC4HDAC2HDAC8HDAC6HDAC3
SCHEMBL5799259 0.80 GSTP1 (0.44) GSTP1TSHRL3MBTL1ALDH1A1MAPT
SCHEMBL15957919 0.80 PTPN1 (0.52) TSHRL3MBTL1CHRM3ALDH1A1MAPT
SCHEMBL10933450 0.78 GSTP1 (0.40) HDAC4HDAC2HDAC8HDAC6HDAC3
SCHEMBL10937960 0.77 CHRM3 (0.45) TSHRL3MBTL1CHRM3ALDH1A1MAPT
SCHEMBL747380 0.75 HIF1A (0.38) HDAC4HDAC2HDAC8HDAC6HDAC3
SCHEMBL11883308 0.74 HIF1A (0.37) HDAC4HDAC2HDAC8HDAC6HDAC3
SCHEMBL44118 0.74
SCHEMBL3369781 0.72 MAPT (0.37) HDAC4HDAC2HDAC8HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003002058-A9 BONE ANABOLIC COMPOUNDS AND METHODS OF USE ANABONIX INC (US) 2004-07-08 WO disclosed
EP-1404344-A2 BONE ANABOLIC COMPOUNDS AND METHODS OF USE Anabonix, Inc. (US) 2004-04-07 EP disclosed
US-20030119800-A1 Bone anabolic compounds and methods of use BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS 2003-06-26 US disclosed
WO-2003002058-A2 BONE ANABOLIC COMPOUNDS AND METHODS OF USE ANABONIX, INC. (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119800-A1 Bone anabolic compounds and methods of use SHBG, BMP2, BMP4 HDAC4 1295/4885HDAC2 4031/4885HDAC8 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.